Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study
Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 402-415
Open Access | Times Cited: 200

Showing 1-25 of 200 citing articles:

Gastric cancer treatment: recent progress and future perspectives
Wen‐Long Guan, Ye He, Rui‐Hua Xu
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 392
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Arndt Vogel, John Bridgewater, Julien Edeline, et al.
Annals of Oncology (2022) Vol. 34, Iss. 2, pp. 127-140
Open Access | Times Cited: 329
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 242
Primary brain tumours in adults
Martin J. van den Bent, Marjolein Geurts, Pim J. French, et al.
The Lancet (2023) Vol. 402, Iss. 10412, pp. 1564-1579
Closed Access | Times Cited: 151
Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study
John Bridgewater, Peter Fletcher, Daniel H. Palmer, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 18, pp. 2048-2057
Open Access | Times Cited: 132
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, et al.
Cancer Treatment Reviews (2023) Vol. 115, pp. 102530-102530
Closed Access | Times Cited: 107
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 8, pp. 925-935
Closed Access | Times Cited: 100
New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 4
Open Access | Times Cited: 96
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 92
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 86
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
Masuko Katoh, Yohann Loriot, Giovanni Brandi, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 312-329
Closed Access | Times Cited: 63
Updated Epidemiology of Gastric Cancer in Asia: Decreased Incidence but Still a Big Challenge
Wing Sum Shin, Fuda Xie, Bonan Chen, et al.
Cancers (2023) Vol. 15, Iss. 9, pp. 2639-2639
Open Access | Times Cited: 57
Pemigatinib in previously treated solid tumors with activating FGFR1–FGFR3 alterations: phase 2 FIGHT-207 basket trial
Jordi Rodón, Silvia Damian, Muhammad Furqan, et al.
Nature Medicine (2024) Vol. 30, Iss. 6, pp. 1645-1654
Open Access | Times Cited: 21
FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
Davide Benedetto Tiz, Luana Bagnoli, Ornelio Rosati, et al.
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2538-2538
Open Access | Times Cited: 49
Futibatinib: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 18, pp. 1737-1743
Open Access | Times Cited: 49
Advances in Diagnosis and Therapy for Bladder Cancer
Xinzi Hu, Guangzhi Li, Song Wu
Cancers (2022) Vol. 14, Iss. 13, pp. 3181-3181
Open Access | Times Cited: 42
Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Olaf Neumann, Timothy C. Burn, Michael Allgäuer, et al.
British Journal of Cancer (2022) Vol. 127, Iss. 8, pp. 1540-1549
Open Access | Times Cited: 42
Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 217-228
Closed Access | Times Cited: 41
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, et al.
Cancers (2023) Vol. 15, Iss. 11, pp. 2899-2899
Open Access | Times Cited: 39
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
Francesco Facchinetti, Antoine Hollebecque, Floriane Brayé, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 1998-2011
Open Access | Times Cited: 39
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric‐Bernstam, James M. Ford, Peter J. O’Dwyer, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 8, pp. 1412-1422
Open Access | Times Cited: 36
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 36
Clinical development and management of adverse events associated with FGFR inhibitors
Vivek Subbiah, Srđan Verstovšek
Cell Reports Medicine (2023) Vol. 4, Iss. 10, pp. 101204-101204
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top